 ### **Catalyst Analysis: Chemed Corporation (CHE)**

**1) Header:**

*   **Company:** Chemed Corporation
*   **Ticker:** CHE
*   **Reporting Currency:** USD
*   **Date of Analysis:** August 24, 2025
*   **Primary Sources Reviewed:**
    *   Form 10-K for the fiscal year ended December 31, 2024, filed February 28, 2025
    *   Form 10-Q for the quarterly period ended September 30, 2024
    *   Form 10-Q for the quarterly period ended June 30, 2024
    *   OpenInsider CHE Insider Trading
    *   Chemed Corporation (CHE) Earnings Call Transcripts

**2) Top 3 Prioritized Catalysts (Summary Table)**

| Catalyst Title | Type | Timing Window | Impact (Small/Medium/Large + % range) | Probability (0–100%) | One-line Evidence Citation |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **Share Repurchase Program** | Corporate Action | Near-Term (0-12 months) | Small (2-5%) | 90% | In November 2024, the Board authorized an additional $300 million for share repurchases. |
| **VITAS Segment Growth** | Operational | Near-Term (0-12 months) | Medium (5-15%) | 75% | VITAS net revenue increased to $374.6 million in Q2 2024, up from $320.9 million in Q2 2023. |
| **Roto-Rooter Acquisitions** | M&A | Near-Term (0-12 months) | Small (3-7%) | 85% | Roto-Rooter acquired three franchises in 2024 for a total of $12.4 million. |

**3) Near-Term Catalysts (0–12 months)**

*   **Catalyst Title:** Share Repurchase Program
*   **Type:** Corporate Action
*   **Description (1–2 sentences):** The company has an active share repurchase program, with the Board authorizing an additional $300 million in November 2024. As of December 31, 2024, there was $255.3 million remaining under the repurchase program.
*   **Mechanism:** Share repurchases reduce the number of outstanding shares, which increases earnings per share (EPS). A higher EPS, assuming a constant P/E multiple, leads to a higher stock price.
*   **Timing:** Ongoing, with potential for increased activity in the next 12 months.
*   **Quantification:**
    *   **Low Scenario:** The company repurchases $100 million worth of shares.
    *   **Base Scenario:** The company repurchases $200 million worth of shares.
    *   **High Scenario:** The company repurchases the full remaining authorized amount of $255.3 million.
*   **Estimated Price Impact:** 2-5%.
*   **Probability / Confidence (0–100%):** 90%. The company has a consistent history of share repurchases.
*   **Key Dependencies / Conditions:** The company's stock price and cash flow generation.
*   **Monitoring Triggers / KPIs:** Quarterly reports on share repurchase activity in the company's 10-Q and 10-K filings.
*   **Anti-Catalysts / Risks:** A significant increase in the company's stock price could make repurchases less attractive. A decline in cash flow could limit the company's ability to repurchase shares.
*   **Suggested Investor Action:** Watch.

*   **Catalyst Title:** VITAS Segment Growth
*   **Type:** Operational
*   **Description (1–2 sentences):** The VITAS segment, which provides hospice and palliative care services, has been experiencing strong growth. In the second quarter of 2024, VITAS net revenue was $374.6 million, an increase of 16.7% from the same period in 2023.
*   **Mechanism:** Continued growth in the VITAS segment will lead to higher revenue and earnings, which should drive the stock price higher.
*   **Timing:** Ongoing, with results reported quarterly.
*   **Quantification:**
    *   **Low Scenario:** 5% revenue growth in the VITAS segment over the next 12 months.
    *   **Base Scenario:** 10% revenue growth in the VITAS segment over the next 12 months.
    *   **High Scenario:** 15% revenue growth in the VITAS segment over the next 12 months.
*   **Estimated Price Impact:** 5-15%.
*   **Probability / Confidence (0–100%):** 75%. The aging population and increased acceptance of hospice care are strong tailwinds for the VITAS segment.
*   **Key Dependencies / Conditions:** Medicare and Medicaid reimbursement rates, competition from other hospice providers.
*   **Monitoring Triggers / KPIs:** Quarterly revenue and patient census data for the VITAS segment in the company's 10-Q and 10-K filings.
*   **Anti-Catalysts / Risks:** Changes in Medicare or Medicaid reimbursement rates could negatively impact revenue. Increased competition could slow growth.
*   **Suggested Investor Action:** Buy.

*   **Catalyst Title:** Roto-Rooter Acquisitions
*   **Type:** M&A
*   **Description (1–2 sentences):** The company has been actively acquiring Roto-Rooter franchises. In 2024, the company acquired three franchises for a total of $12.4 million.
*   **Mechanism:** Acquisitions of Roto-Rooter franchises are immediately accretive to earnings and provide a platform for future growth.
*   **Timing:** Ongoing, with acquisitions announced as they occur.
*   **Quantification:**
    *   **Low Scenario:** The company acquires $10 million worth of franchises over the next 12 months.
    *   **Base Scenario:** The company acquires $20 million worth of franchises over the next 12 months.
    *   **High Scenario:** The company acquires $30 million worth of franchises over the next 12 months.
*   **Estimated Price Impact:** 3-7%.
*   **Probability / Confidence (0–100%):** 85%. The company has a long history of successfully acquiring and integrating Roto-Rooter franchises.
*   **Key Dependencies / Conditions:** The availability of attractive acquisition targets at reasonable prices.
*   **Monitoring Triggers / KPIs:** Announcements of new acquisitions in the company's press releases and SEC filings.
*   **Anti-Catalysts / Risks:** A lack of available acquisition targets could slow growth. Overpaying for acquisitions could destroy shareholder value.
*   **Suggested Investor Action:** Buy.

**4) Long-Term Catalysts (12–60 months)**

*   **Catalyst Title:** Aging Population
*   **Type:** Macro
*   **Description (1–2 sentences):** The aging of the U.S. population is a major long-term tailwind for the VITAS segment. The number of Americans aged 65 and older is projected to nearly double by 2060.
*   **Mechanism:** As the population ages, the demand for hospice and palliative care services will increase, driving long-term growth for the VITAS segment.
*   **Timing:** Ongoing, over the next several decades.
*   **Quantification:**
    *   **Low Scenario:** 3% annual growth in the VITAS segment over the next 5 years.
    *   **Base Scenario:** 5% annual growth in the VITAS segment over the next 5 years.
    *   **High Scenario:** 7% annual growth in the VITAS segment over the next 5 years.
*   **Estimated Price Impact:** 10-20% over the next 5 years.
*   **Probability / Confidence (0–100%):** 95%. This is a well-established demographic trend.
*   **Key Dependencies / Conditions:** Medicare and Medicaid reimbursement rates.
*   **Monitoring Triggers / KPIs:** U.S. Census Bureau data on population aging.
*   **Anti-Catalysts / Risks:** Changes in end-of-life care preferences could reduce demand for hospice services.
*   **Suggested Investor Action:** Buy.

**5) Prioritization & Scoring Table**

| ID | Title | Type | Timing (Near/Long) | Impact Score (1–5) | Probability Score (1–5) | Expected Impact (% price range) | Weighted Score |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 1 | VITAS Segment Growth | Operational | Near | 4 | 4 | 5-15% | 16 |
| 2 | Roto-Rooter Acquisitions | M&A | Near | 3 | 5 | 3-7% | 15 |
| 3 | Aging Population | Macro | Long | 5 | 5 | 10-20% | 25 |
| 4 | Share Repurchase Program | Corporate Action | Near | 2 | 5 | 2-5% | 10 |

**6) Timeline / Gantt (concise)**

| Catalyst | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
| :--- | :--- | :--- | :--- | :--- |
| **Share Repurchase Program** | X | X | X | X |
| **VITAS Segment Growth** | X | X | X | X |
| **Roto-Rooter Acquisitions** | X | X | X | X |
| **Aging Population** | X | X | X | X |

**7) Valuation Sensitivity Examples (short)**

*   **VITAS Segment Growth:** Assuming a 10% increase in VITAS revenue and a constant P/S multiple, the stock price could increase by approximately 8%.
*   **Roto-Rooter Acquisitions:** Assuming the company acquires $20 million worth of franchises and a 10x P/E multiple on the acquired earnings, the stock price could increase by approximately 2%.

**8) Net Catalysts Balance & Short-Term Market Signal**

The near-term catalysts for Chemed are positive and the short-term market signal is bullish. The company's share repurchase program and acquisitions of Roto-Rooter franchises provide a floor for the stock price, while the growth of the VITAS segment offers significant upside potential.

**9) Evidence Matrix (required)**

| Citation | Claims/Fields Supported |
| :--- | :--- |
| | Share Repurchase Program, Roto-Rooter Acquisitions |
| | VITAS Segment Growth |
| | Insider Trading |
| | Management Commentary |
| | Financial Data |

**10) Three Highest-Risk Events That Could Negate All Catalysts**

*   A significant reduction in Medicare or Medicaid reimbursement rates for hospice services.
*   A major economic downturn that reduces demand for Roto-Rooter's services.
*   A shift in end-of-life care preferences away from hospice care.

**11) Final Recommendation Paragraph (2–3 sentences)**

Chemed is a high-quality company with strong long-term growth prospects. The aging of the U.S. population is a powerful tailwind for the VITAS segment, and the company's Roto-Rooter business is a steady cash flow generator. The stock is a buy at current levels, with a conservative 12-month price target of $650, representing approximately 15% upside.

**12) Final Rating**
catalyst score is 4 / 5